Back to Search
Start Over
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.
- Source :
-
Vaccine [Vaccine] 2011 Oct 06; Vol. 29 (43), pp. 7514-22. Date of Electronic Publication: 2011 Apr 16. - Publication Year :
- 2011
-
Abstract
- We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. The vaccines were safe but interferon-γ ELISPOT responses were low compared to other poxvirus vectors, despite targeting multiple antigens. There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene.<br /> (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Subjects :
- Adolescent
Adult
Antibodies, Protozoan immunology
Antigens, Protozoan immunology
Humans
Immunization, Secondary
Interferon-gamma biosynthesis
Malaria, Falciparum immunology
Malaria, Falciparum prevention & control
Middle Aged
Treatment Outcome
Vaccination
Vaccines, Subunit administration & dosage
Vaccines, Subunit adverse effects
Vaccines, Subunit immunology
Young Adult
Malaria Vaccines administration & dosage
Malaria Vaccines adverse effects
Malaria Vaccines immunology
Plasmodium falciparum immunology
Polyproteins immunology
Protozoan Proteins immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2518
- Volume :
- 29
- Issue :
- 43
- Database :
- MEDLINE
- Journal :
- Vaccine
- Publication Type :
- Academic Journal
- Accession number :
- 21501642
- Full Text :
- https://doi.org/10.1016/j.vaccine.2011.03.083